IDEAL_ANSWER:
- Patients who carry somatic activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene, respond well to erlotinib and gefitinib.

EXACT_ANSWER:
- epidermal growth factor receptor (EGFR) gene